Samsung Biologics and LegoChem Biosciences Collaborate to Develop and Manufacture ADC Programs
Shots:
- Samsung Biologics and LegoChem Biosciences have entered into a partnership agreement for the development and manufacturing of antibody-drug conjugate (ADC) programs
- As per the agreement, Samsung Biologics will offer antibody development and drug substance manufacturing services for LegoChem Biosciences' ADC program targeting solid tumors
- LegoChem Biosciences anticipates IND submission to the US FDA by H1’25 with pre-clinical results demonstrating the effectiveness
Ref: Biogen | Image: Samsung Biologics
Related News:- Biogen Entered into an Agreement with Samsung Biologics to Sell Equity Stake in Biosimilar Joint Venture for ~$2.3B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
